Literature DB >> 16444900

Memory effects of benzodiazepines: memory stages and types versus binding-site subtypes.

Miroslav M Savić1, Dragan I Obradović, Nenad D Ugresić, Dubravko R Bokonjić.   

Abstract

Benzodiazepines are well established as inhibitory modulators of memory processing. This effect is especially prominent when applied before the acquisition phase of a memory task. This minireview concentrates on the putative subtype selectivity of the acquisition-impairing action of benzodiazepines. Namely, recent genetic studies and standard behavioral tests employing subtype-selective ligands pointed to the predominant involvement of two subtypes of benzodiazepine binding sites in memory modulation. Explicit memory learning seems to be affected through the GABAA receptors containing the alpha1 and alpha5 subunits, whereas the effects on procedural memory can be mainly mediated by the alpha1 subunit. The pervading involvement of the alpha1 subunit in memory modulation is not at all unexpected because this subunit is the major subtype, present in 60% of all GABAA receptors. On the other hand, the role of alpha5 subunits, mainly expressed in the hippocampus, in modulating distinct forms of memory gives promise of selective pharmacological coping with certain memory deficit states.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16444900      PMCID: PMC2565469          DOI: 10.1155/NP.2005.289

Source DB:  PubMed          Journal:  Neural Plast        ISSN: 1687-5443            Impact factor:   3.599


  10 in total

1.  Amygdala-specific reduction of alpha1-GABAA receptors disrupts the anticonvulsant, locomotor, and sedative, but not anxiolytic, effects of benzodiazepines in mice.

Authors:  Scott A Heldt; Kerry J Ressler
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

2.  Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database.

Authors:  Francois Chavant; Sylvie Favrelière; Claire Lafay-Chebassier; Caroline Plazanet; Marie-Christine Pérault-Pochat
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care.

Authors:  Joseph A Lieberman
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 4.  Contribution of sedative-hypnotic agents to delirium via modulation of the sleep pathway.

Authors:  Robert D Sanders; Mervyn Maze
Journal:  Can J Anaesth       Date:  2010-12-18       Impact factor: 5.063

5.  Negative Emotional Arousal Impairs Associative Memory Performance for Emotionally Neutral Content in Healthy Participants.

Authors:  Jonathan Guez; Rotem Saar-Ashkenazy; Liran Mualem; Matan Efrati; Eldad Keha
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

Review 6.  Patient-reported outcomes in post-traumatic stress disorder. Part II: focus on pharmacological treatment.

Authors:  Hans-Peter Kapfhammer
Journal:  Dialogues Clin Neurosci       Date:  2014-06       Impact factor: 5.986

Review 7.  Neurobiology of memory and anxiety: from genes to behavior.

Authors:  Allan V Kalueff
Journal:  Neural Plast       Date:  2007-01-10       Impact factor: 3.599

8.  The Effect of Trier Social Stress Test (TSST) on Item and Associative Recognition of Words and Pictures in Healthy Participants.

Authors:  Jonathan Guez; Rotem Saar-Ashkenazy; Eldad Keha; Chen Tiferet-Dweck
Journal:  Front Psychol       Date:  2016-04-12

9.  The impact of threat of shock-induced anxiety on memory encoding and retrieval.

Authors:  Sorcha Bolton; Oliver J Robinson
Journal:  Learn Mem       Date:  2017-09-15       Impact factor: 2.460

10.  Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia.

Authors:  Miren Ettcheto; Jordi Olloquequi; Elena Sánchez-López; Oriol Busquets; Amanda Cano; Patricia Regina Manzine; Carlos Beas-Zarate; Rubén D Castro-Torres; Maria Luisa García; Mónica Bulló; Carme Auladell; Jaume Folch; Antonio Camins
Journal:  Front Aging Neurosci       Date:  2020-01-08       Impact factor: 5.750

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.